Ketorolac Tromethamine
Blood and Marrow Transplant (BMT)
Stanford UniversityPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Blood and Marrow Transplant (BMT) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evomela Stanford University | Phase 2 | B |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Stanford University | Phase 2 | B |
FENTANYL Stanford University | Phase 2 | B |
Monomethyl Fumarate Stanford University | Phase 2 | B |
Cyclophosphamide Stanford University | Phase 2 | B |
HYDROMORPHON Stanford University | Phase 2 | B |
Dc-Cik Stanford University | Phase 1 | CC |
Same molecule, other indications
Ketorolac Tromethamine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →